Share-based Payment Arrangement, Expense of iTeos Therapeutics, Inc. from 30 Jun 2019 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
iTeos Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2019 to 30 Jun 2025.
  • iTeos Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2025 was $5,880,000, a 27% decline year-over-year.
  • iTeos Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2025 was $27,131,000, a 8.3% decline year-over-year.
  • iTeos Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $29,941,000, a 11% increase from 2023.
  • iTeos Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $27,021,000, a 25% increase from 2022.
  • iTeos Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $21,561,000, a 56% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

iTeos Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $27,131,000 $5,880,000 -$2,182,000 -27% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $29,313,000 $6,635,000 -$628,000 -8.6% 01 Jan 2025 31 Mar 2025 10-Q 28 Apr 2025 2025 Q1
Q4 2024 $29,941,000 $7,073,000 -$120,000 -1.7% 01 Oct 2024 31 Dec 2024 10-K 05 Mar 2025 2024 FY
Q3 2024 $30,061,000 $7,543,000 +$486,000 +6.9% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2024 2024 Q3
Q2 2024 $29,575,000 $8,062,000 +$1,098,000 +16% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $28,477,000 $7,263,000 +$1,456,000 +25% 01 Jan 2024 31 Mar 2024 10-Q 28 Apr 2025 2025 Q1
Q4 2023 $27,021,000 $7,193,000 +$1,308,000 +22% 01 Oct 2023 31 Dec 2023 10-K 05 Mar 2025 2024 FY
Q3 2023 $25,713,000 $7,057,000 +$1,334,000 +23% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $24,379,000 $6,964,000 +$1,204,000 +21% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $23,175,000 $5,807,000 +$1,614,000 +38% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q4 2022 $21,561,000 $5,885,000 +$1,844,000 +46% 01 Oct 2022 31 Dec 2022 10-K 06 Mar 2024 2023 FY
Q3 2022 $19,717,000 $5,723,000 +$1,781,000 +45% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $17,936,000 $5,760,000 +$2,533,000 +78% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $15,403,000 $4,193,000 +$1,609,000 +62% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $13,794,000 $4,041,000 +$1,999,000 +98% 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2024 2023 FY
Q3 2021 $11,795,000 $3,942,000 +$2,228,000 +130% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $9,567,000 $3,227,000 +$2,877,000 +822% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $6,690,000 $2,584,000 +$2,398,000 +1289% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $4,292,000 $2,042,000 01 Oct 2020 31 Dec 2020 10-K 23 Mar 2022 2021 FY
Q3 2020 $1,714,000 +$1,513,000 +753% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $350,000 +$147,000 +72% 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021 2021 Q2
Q1 2020 $186,000 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q3 2019 $201,000 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $203,000 01 Apr 2019 30 Jun 2019 10-Q 01 Sep 2020 2020 Q2

iTeos Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $29,941,000 +$2,920,000 +11% 01 Jan 2024 31 Dec 2024 10-K 05 Mar 2025 2024 FY
2023 $27,021,000 +$5,460,000 +25% 01 Jan 2023 31 Dec 2023 10-K 05 Mar 2025 2024 FY
2022 $21,561,000 +$7,767,000 +56% 01 Jan 2022 31 Dec 2022 10-K 06 Mar 2024 2023 FY
2021 $13,794,000 +$9,502,000 +221% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2024 2023 FY
2020 $4,292,000 +$3,483,000 +431% 01 Jan 2020 31 Dec 2020 10-K 23 Mar 2022 2021 FY
2019 $809,000 01 Jan 2019 31 Dec 2019 10-K 24 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.